Compare Verisign, Inc. (VRSN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Verisign, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Verisign, Inc. trades at $277.5 (market cap $25.26B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Verisign, Inc. pays a 1.17% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Verisign, Inc. nearer its low. Which is the better fit depends on your goals.
| VRSN | XBI | |
|---|---|---|
Market Cap | $25.26B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $310.00 | $164.28 |
52-Week Low | $211.49 | $85.16 |
Enterprise Value | $26.50B | — |
Dividend Yield | 1.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
